Cargando…

Monocytes and neutrophils in the inflammatory cascade of systemic onset Juvenile Idiopathic Arthritis

Detalles Bibliográficos
Autores principales:	ter Haar, N, de Jager, W, Scholman, R, Leliefeld, P, Tak, T, Vastert, B, de Roock, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597283/ http://dx.doi.org/10.1186/1546-0096-13-S1-O54

Ejemplares similares

IL-18 production upon s100 stimulation is reduced in active sJIA patients compared to sJIA patients in remission and healthy controls
por: Haar, Nienke Ter, et al.
Publicado: (2014)

The human microbiome and juvenile idiopathic arthritis
por: Verwoerd, Anouk, et al.
Publicado: (2016)

4.5 Defective phosphorylation of the interleukin 18 receptor beta-chain causes impaired NK cell function in systemic onset Juvenile Idiopathic Arthritis
por: de Jager, W, et al.
Publicado: (2008)

PReS-FINAL-2181: Recombinant il-1ra restores the il-18-nk cell axis in steroid naive systemic juvenile idiopathic arthritis
por: De Jager, W, et al.
Publicado: (2013)

PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis
por: Vastert, S, et al.
Publicado: (2013)

Recombinant IL1-RA in the early phase of systemic onset JIA: before the onset of arthritis
por: Vastert, SJ, et al.
Publicado: (2011)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

Patients with early-onset systemic juvenile idiopathic arthritis show more inflammation and worse outcome
por: Russo, R, et al.
Publicado: (2011)

Whole exome sequencing in systemic juvenile idiopathic arthritis
por: Moghaddas, F, et al.
Publicado: (2015)

Etanercept in juvenile idiopathic arthritis: Who will benefit?
por: Otten, MH, et al.
Publicado: (2011)

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis
por: Van Dijkhuizen, Pieter E H, et al.
Publicado: (2011)

3.4 Physical activity in adolescents with juvenile idiopathic arthritis
por: Lelieveld, OTHM, et al.
Publicado: (2008)

Effectiveness of adalimumab in the treatment of juvenile idiopathic arthritis associated with uveitis
por: Zholobova, Elena, et al.
Publicado: (2014)

Methotrexate does not primarily affect Foxp3+ regulatory T cells in poly-articular juvenile idiopathic arthritis
por: Vastert, SJ, et al.
Publicado: (2008)

Juvenile idiopathic arthritis is associated with potentially pathogenic glycosylation of IgG
por: Ercan, Altan, et al.
Publicado: (2012)

Immunomodulatory actions of methotrexate on T cells in juvenile idiopathic arthritis
por: Ćalasan, Maja Bulatović, et al.
Publicado: (2012)

Preliminary study of regionalised centre-of-pressure analysis in patients with juvenile idiopathic arthritis
por: Hendry, Gordon J, et al.
Publicado: (2012)

14.3 Early cardiovascular risk assessment in patients with juvenile idiopathic arthritis
por: Vlahos, AP, et al.
Publicado: (2008)

14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
por: Hunter, PJ, et al.
Publicado: (2008)

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013)

Methotrexate restores effector T cell responsiveness in juvenile idiopathic arthritis
por: Bulatović, Maja, et al.
Publicado: (2011)

Akinra restores the defective IL-18 NK cell axis in steroid naïve systemic onset JIA patients
por: de Jager, W, et al.
Publicado: (2011)

3.5 Comparison of functional ability in juvenile idiopathic arthritis, juvenile dermatomyositis, juvenile systemic lupus erythematosus and healthy controls. An analysis of the PRINTO database
por: Filocamo, G, et al.
Publicado: (2008)

A family carrying a homozygous LACC1 truncated mutation expands the clinical phenotype of this disease beyond systemic-onset juvenile idiopathic arthritis
por: Arostegui, JI, et al.
Publicado: (2015)

Musculoskeletal ultrasound versus magnetic resonance in supporting clinical management of juvenile idiopathic arthritis
por: Lanni, Stefano, et al.
Publicado: (2014)

Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Minoia, Francesca, et al.
Publicado: (2014)

Systemic juvenile idiopathic arthritis is associated with HLA-DRB1 in Europeans and Americans of European descent
por: Ombrello, Michael, et al.
Publicado: (2012)

The risk and nature of flares in juvenile idiopathic arthritis: results from the reACCh-Out cohort
por: Guzman, Jaime, et al.
Publicado: (2014)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Mesenchymal stromal cells suppress synovial fluid-derived t cells from juvenile idiopathic arthritis patients in vitro
por: Wienke, J, et al.
Publicado: (2014)

Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study
por: ter Haar, Nienke M., et al.
Publicado: (2019)

2.1 Long-term safety and efficacy of tocilizumab in children with systemic juvenile idiopathic arthritis (JIA)
por: Yokota, S, et al.
Publicado: (2008)

Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2011)

Safety and efficacy of ultrasound guided corticosteroid injections into temporomandibular joints in children with active juvenile idiopathic arthritis
por: Habibi, S, et al.
Publicado: (2011)

Two year remission rates and functional outcomes in an inception cohort of Canadian children with juvenile idiopathic arthritis
por: Tse, Shirley ML, et al.
Publicado: (2012)

YIM-O13. Development of novel protein biomarkers for the prediction of response to treatment in juvenile idiopathic arthritis
por: Palman, Jason, et al.
Publicado: (2014)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

2.4 Magnetic resonance imaging, ultrasonography and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis
por: Malattia, C, et al.
Publicado: (2008)

Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Davì, Sergio, et al.
Publicado: (2011)

Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study
por: De Benedetti, F, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m5lis8vo7un9rbou184htpqr89